You are viewing the site in preview mode

Skip to main content


Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Article metrics

The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:68


After the publication of the article [1], the treatment algorithm for advanced/metastatic bladder cancer in Fig. 3 was updated to reflect the current use of immunotherapy in this setting. The correct Fig. 3 can be seen here and the original article has been updated to reflect this change.

Fig. 3

All of the treatment options shown may be appropriate. The selection of therapy should be individualized based on patient eligibility and the availability of therapy, at the discretion of the treating physician. These algorithms represent the consensus recommendations of the Task Force. (1) Atezolizumab and pembrolizumab are FDA approved for patients with metastatic urothelial carcinoma who are ineligible to receive cisplatin. (2) Atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab are FDA approved for advanced disease that has worsened on platinum containing regimens or within 12 months of receiving a platinum-containing regimen before (neoadjuvant) or after surgery (adjuvant). Abbreviations: dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DDMVAC)


  1. 1.

    Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Journal for Immunotherapy of Cancer. 2017;5:68.

Download references

Author information

Correspondence to Ashish M. Kamat.

Additional information

The online version of the original article can be found under doi:10.1186/s40425-017-0271-0

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark